- Home
- TAC vs KNSA Comparison
TAC vs KNSA Comparison
Compare TAC & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TAC | KNSA |
|---|---|---|
| Founded | 1909 | 2015 |
| Country | Canada | United Kingdom |
| Employees | 1350 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | TAC | KNSA |
|---|---|---|
| Price | $12.58 | $54.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $23.67 | ★ $60.86 |
| AVG Volume (30 Days) | ★ 832.7K | 795.8K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | N/A | $37.48 |
| Revenue Next Year | $6.48 | $17.87 |
| P/E Ratio | ★ N/A | $198.13 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $8.34 | $25.71 |
| 52 Week High | $17.88 | $54.31 |
Technical Indicators
Market Signals| Indicator | TAC | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 46.09 | 71.26 |
| Support Level | $12.06 | $40.67 |
| Resistance Level | $12.65 | N/A |
| Average True Range (ATR) | 0.48 | 2.27 |
| MACD | -0.06 | 1.15 |
| Stochastic Oscillator | 32.58 | 96.82 |
Price Performance
Historical ComparisonAbout TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse electrical power generation assets in Canada, the United States, and Western Australia. The company has reportable segments namely, Hydro, Wind & Solar, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.